Phio Pharmaceuticals Corp. 8-K Filing - Mar 30

The Big Picture

Phio Pharmaceuticals Corp. filed an 8-K with the SEC on Mar 30, 2026, reporting Item 8.01, Other Events. For investors, the immediate takeaway is that a formal disclosure has been made, but the filing as indexed provides only the filing metadata at this time.

Because the company noted Item 8.01, the filing could contain developments material to shareholders, but the SEC index entry itself lists the record details rather than a narrative of the event. Investors should register the filing and wait for any follow-up disclosures or market reaction.

What's Happening

The SEC archive shows a new Form 8-K for Phio Pharmaceuticals Corp. with the following recorded data points. Each figure is drawn from the SEC index entry for the filing and helps you verify and track the disclosure.

• Filed date: 2026-03-30, confirming the company officially submitted the report to the SEC on that date.
• CIK / Identifier: 0001533040, the company identifier used in the SEC system.
• Accession No.: 0001437749-26-010164, the unique accession number for this specific filing in the SEC archive.
• File size: 175 KB, as shown in the SEC index metadata for the filing package.

The entry is categorized under Item 8.01, Other Events. The SEC index provides these facts but does not embed a text summary of the event in the index line itself. Investors should consult the full 8-K document at the SEC link for any narrative details or attachments that explain the nature of the "Other Events" disclosed.

Why It Matters For Your Portfolio

An 8-K reporting Item 8.01 can be a placeholder for many kinds of developments, ranging from corporate announcements to operational updates. Because Phio Pharmaceuticals Corp. has filed such a report, shareholders should treat the filing as a potential catalyst and confirm whether the full document contains substantive disclosures that could influence valuation or risk.

Who should pay attention: active traders and investors who follow small-cap and biotech news should monitor the full 8-K. Long-term shareholders may want to review the filing for any strategic or regulatory developments that could change the company outlook. At this stage, the indexed record itself supplies the filing metadata but not the full substance of the event.

Risks To Consider

• Information Gap, the SEC index entry lists the filing but does not summarize content. The lack of immediate detail means you may briefly face uncertainty until the full 8-K narrative is reviewed.
• Market Reaction, if the event disclosed in Item 8.01 is material, share price volatility could follow. That risk is conditional on the substance of the filing, which the index does not state.
• Timing and Follow-Up, the company may file additional reports or amendments. Relying on the index alone could miss important clarifications or corrections in subsequent filings.

What To Watch Next

To turn this indexed filing into actionable insight, monitor the official 8-K content and any company or market responses. Key items to watch are listed below.

• Full 8-K text at the SEC link associated with Accession No. 0001437749-26-010164, to read the Item 8.01 disclosure in full.
• Company press releases or investor relations statements that reference the Mar 30 filing, for clarification or additional details.
• Subsequent SEC filings, including amendments or 8-Ks with related items that expand on the initial disclosure.
• Market volume and price action in Phio-related securities following any substantive disclosure, if and when details are published.

The Bottom Line

• Phio Pharmaceuticals Corp. filed an 8-K on Mar 30, 2026, listed under Item 8.01 Other Events; the SEC index entry provides the filing metadata but not the narrative.
• Investors should open the full 8-K using Accession No. 0001437749-26-010164 to determine whether the disclosed event is material to valuation or risk.
• Expect possible market movement if the Item 8.01 disclosure contains substantive news; monitor company statements and follow-up filings.
• Use caution while details remain limited; this article summarizes the filing metadata and suggests where to look for definitive information.

FAQ

Q: What did Phio Pharmaceuticals Corp. disclose in the 8-K?

A: The SEC index entry records that an 8-K was filed on 2026-03-30 under Item 8.01 Other Events, with Accession No. 0001437749-26-010164 and a file size of 175 KB. The index line itself does not include narrative details; see the full 8-K document for the disclosure text.

Q: Where can I view the complete filing?

A: You can retrieve the full 8-K by searching the SEC filings for Accession No. 0001437749-26-010164 or the company CIK 0001533040 on the SEC EDGAR website to read the Item 8.01 text and any exhibits.

Q: Should I change my position based on this filing?

A: This summary only reports the filing metadata. Decisions about positions should be based on the substantive information in the full 8-K and your own investment objectives. This article does not provide personalized investment advice.